We discovered four compounds that inhibit the infectivity of an amantadine-resistant strain of the influenza A virus. The compounds came out in in silico screening for binders of the M2 proton channel of the virus and it is therefore reasonable to assume that their mode of operation is based on blocking this channel, which is also the target of amantadine. Ultimately, these compounds could lead to discovery of new anti-flu drugs. They could be complementary to the Tamiflu drug, targeting the neuraminidase envelop protein of the virus, which is the commonly used treatment for flu.
Project ID : 10-2014-784
Additional information can be provided upon request.
Project manager
Elisha Natan
Director BD
Project researchers
Nir Ben-Tal
T.A.U Tel Aviv University, Life Sciences
The Department of Biochemistry and Molecular Biology
Ramot is Tel Aviv University's (TAU) technology transfer company and its liaison to industry, bringing promising scientific discoveries made at the university to industry's attention. The company provides the legal and commercial frameworks for inventions made by TAU faculty, students and researchers, protecting discoveries with patents and working jointly with industry to bring scientific innovations to the market.
Create your free account to connect with RAMOT at Tel Aviv University Ltd. and thousands of other innovative organizations and professionals worldwide
Send a request for information
to RAMOT at Tel Aviv University Ltd.
Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.
Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support
